1. BUSINESS OVERVIEW
Idenix Pharmaceuticals, Inc., which we refer to together with our wholly owned subsidiaries as Idenix, we, us or our, is a biopharmaceutical company engaged in the discovery and development of drugs for
the treatment of human viral diseases with operations in the United States and France. Currently, our primary research and development focus is on the treatment of patients with hepatitis C virus, or HCV, using nucleoside/nucleotide polymerase
inhibitors and NS5A inhibitors.
We have incurred losses in each year since our inception and at March 31, 2012, we had
an accumulated deficit of $664.3 million. In the three months ended March 31, 2012, we reported net income due to the recognition of $36.1 million of deferred revenue related to the termination of a license agreement with ViiV Healthcare
Company, or ViiV. However, we expect to report a net loss for the year ending December 31, 2012 and for the next several years as we continue to expand our drug discovery and development efforts. As a result of continuing losses, we may seek
additional funding through a combination of public or private financing, collaborative relationships or other arrangements and we may seek a partner who will assist in the future development and commercialization of IDX184, our lead nucleotide drug
candidate. In October 2011, we filed a universal shelf registration statement with the Securities and Exchange Commission, or SEC, which will allow us to offer and sell from time to time up to a maximum of $150.0 million of shares of common
stock, at prices and terms to be determined at the time of sale. As of March 31, 2012, we had approximately $88.9 million remaining for issuance of common stock under this shelf registration. Any financing requiring the issuance of additional
shares of capital stock must first be approved by Novartis Pharma AG, or Novartis, so long as Novartis continues to own at least 19.4% of our voting stock. Additional funding may not be available to us or, if available, may not be on terms favorable
to us. Further, any additional equity financing may be dilutive to stockholders, other than Novartis, which has the right to maintain its current ownership level. As of April 23, 2012, Novartis owned approximately 31% of our outstanding common
We believe that our current cash, cash equivalents and the expected royalty payments associated
with product sales of Tyzeka®/Sebivo
® will be sufficient to sustain operations through at least December 31, 2012. If we are unable to obtain adequate financing on a timely basis, we could be
required to delay, reduce or eliminate one or more of our drug development programs, enter into new collaborative, strategic alliances or licensing arrangements that may not be favorable to us and reduce the number of our employees. More generally,
if we are unable to obtain adequate funding, we may be required to scale back, suspend or terminate our business operations. We are subject to risks common to companies in the biopharmaceutical industry including, but not limited to, the successful
development of products, clinical trial uncertainty, regulatory approval, fluctuations in operating results and financial risks, potential need for additional funding, protection of proprietary technology and patent risks, compliance with government
regulations, dependence on key personnel and collaboration partners, competition, technological and medical risks and management of growth.
Basis of Presentation
The condensed consolidated financial statements reflect the operations of Idenix Pharmaceuticals, Inc. and our wholly owned subsidiaries.
All intercompany accounts and transactions have been eliminated in consolidation.
The accompanying condensed consolidated
financial statements are unaudited and have been prepared by us in accordance with generally accepted accounting principles in the United States of America, or GAAP, for interim reporting. Accordingly, these interim financial statements do not
include all the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2011, which are included in our
Annual Report on Form 10-K filed with the SEC on March 6, 2012. These interim financial statements are unaudited, but in the opinion of management, reflect all adjustments (including normal recurring accruals) necessary for a fair statement of
the financial position and results of operations for the interim periods presented. The year ended consolidated balance sheet data presented for comparative purposes was derived from audited financial statements, but does not include all disclosures
required by GAAP.
The preparation of condensed consolidated financial statements in accordance with GAAP requires management
to make estimates and judgments that may affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures of contingent assets and liabilities. On an on-going basis, we evaluate our estimates, judgments and
methodologies, including those related to revenue recognition, our collaborative relationships, clinical trial expenses, impairment and amortization of long-lived assets including intangible assets, share-based compensation, income taxes including
the valuation allowance for deferred tax assets, contingencies and litigation. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making
judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions.
The results of
operations for the interim periods are not necessarily indicative of the results of operations to be expected for any future period or the fiscal year ending December 31, 2012.